Polymers and Biomaterials Field, Research Center for Functional Materials, National Institute for Materials Science, 1-1 Namiki, Tsukuba, Ibaraki 305-0044, Japan.
J Mater Chem B. 2023 May 10;11(18):4005-4013. doi: 10.1039/d3tb00424d.
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder characterized by immune system dysfunction. Despite the availability of various anti-inflammatory drugs, they exhibit low therapeutic efficacy with systemic side effects. In this study, we developed oral anti-inflammatory polyamine-based nanomedicines for the treatment of ulcerative colitis. Polyamine-bearing nanoparticles were prepared by the self-assembly of hyaluronic acid in organic solvents and crosslinking with branched oligoethyleneimine. Polyamine nanoparticles were found to suppress excessive inflammatory responses by scavenging the reactive oxygen species (ROS). Moreover, these nanoparticles inhibited enzymatic degradation and targeting of inflamed intestinal tissues. Additionally, they suppressed the inflammatory responses and recovered the pathological disorders in the colon of an ulcerative colitis mouse model. Therefore, polyamine-based nanomedicines exhibit great potential as biocompatible ROS-scavenging drugs for the treatment of IBD.
炎症性肠病（IBD）是一种慢性炎症性疾病，其特征是免疫系统功能障碍。尽管有各种抗炎药物，但它们的治疗效果不佳，且具有全身副作用。在这项研究中，我们开发了用于治疗溃疡性结肠炎的口服抗炎多胺基纳米药物。多胺载药纳米粒通过透明质酸在有机溶剂中的自组装和分支聚亚乙基亚胺的交联制备而成。研究发现，多胺纳米粒通过清除活性氧（ROS）来抑制过度的炎症反应。此外，这些纳米粒还抑制了酶促降解和靶向炎症肠道组织。此外，它们还抑制了溃疡性结肠炎小鼠模型结肠中的炎症反应并恢复了病理紊乱。因此，多胺基纳米药物作为生物相容性的 ROS 清除药物，具有治疗 IBD 的巨大潜力。
